CR
CRRVF.US CVR Medical Corp
- Market cap
- USD 1.07K
- P/E
- -
- P/B
- 12.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is CRRVF.US undervalued?
Graham numberThe Graham number of CVR Medical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CVR Medical Corp fundamental analysis
No fundamental analysis for CVR Medical Corp yet.
CVR Medical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CVR Medical Corp
CVR Medical Corp., a med-tech organization, engages in the development of technology for the healthcare sector. The company provides carotid stenotic scan device, a diagnostic tool to detect and measure carotid arterial stenosis. It offers its products for patients, payors, and healthcare providers. CVR Medical Corp. was incorporated in 1980 and is based in North Vancouver, Canada.
Full company profileCVR Medical Corp financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
CVR Medical Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -275.00 | -226.00 | -239.00 | -244.00 | -245.00 | - | - |
| Operating Income | -153K | -127K | -128K | -1.85M | -5.12M | -6.90M | -5.24M | -87.4K | -588K | - | - |
| EBITDA | -130K | -127K | -128K | -1.85M | -5.12M | -8.66M | -6.43M | -43.5K | -685K | - | - |
| Net Income | -128K | -127K | -173K | -2.24M | -6.75M | -7.44M | -5.26M | -173K | -1.80M | - | - |
| EPS | -0.01 | -0.01 | -0.01 | -0.08 | -0.12 | -0.10 | -0.05 | 0.00 | -0.02 | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 14.2K | 5.27K | 10.9K | 1.21M | 1.72M | 1.38M | 1.21M | 1.22M | 97.6K | - | - |
| Total Liabilities | 173K | 278K | 345K | 215K | 108K | 1.17M | 3.43M | 3.91M | 4.55M | - | - |
| Shareholders' Equity | -169K | -272K | -334K | 999K | 1.61M | 212K | -2.22M | -2.69M | -4.46M | - | - |
| Cash & Short-term Investments | 633.00 | 770.12 | 6.73K | 132K | 463K | 74.7K | 3.23K | 3.45K | 94.4K | - | - |
| Total Debt | - | - | - | - | - | 25.0K | 145K | 619K | 774K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -130K | -140K | -16.5K | -1.21M | -8.59M | -4.36M | -2.08M | -180K | -88.4K | - | - |
| Capital Expenditure | 0.00 | 1.55K | 1.23K | 1.23K | 1.57K | 0.00 | 0.00 | 0.00 | 3.91 | 0.00 | - |
| Free Cash Flow | -130K | -140K | -173K | -3.02M | -8.59M | -4.36M | -2.08M | -180K | -88.4K | - | - |
| Ratios | |||||||||||
| ROE | - | - | - | -224.0% | -418.4% | -3,517.3% | - | - | - | - | - |
| ROA | -905.9% | -2,405.4% | -1,587.2% | -184.3% | -392.1% | -538.3% | -434.5% | -14.2% | -1,845.7% | - | - |
| Debt to Equity | - | - | - | - | - | 0.12x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
CVR Medical Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 2.02M | 0.02 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
| 2013 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CVR Medical Corp
- Insiders 29.28%
- Institutions 0.00%
- Public & others 70.72%
- Shares outstanding 107M
- Free float 93.5M
CVR Medical Corp company profile
- Company name
- CVR Medical Corp
- Ticker
- CRRVF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 221 West Esplanade, North Vancouver, BC, Canada, V7M 3J3
- Phone
- 757-909-0491
- Website
- cvrmed.com
About CVR Medical Corp
CVR Medical Corp., a med-tech organization, engages in the development of technology for the healthcare sector. The company provides carotid stenotic scan device, a diagnostic tool to detect and measure carotid arterial stenosis. It offers its products for patients, payors, and healthcare providers. CVR Medical Corp. was incorporated in 1980 and is based in North Vancouver, Canada.
CVR Medical Corp management
6- Dr. Paul S. Blunden M.D.President, Director, Medical Advisor & CFO
- Mr. Philip Bendick Ph.D.Medical Advisor & Independent Board Director
- Mr. Darren DayChief Executive Officer
- Dr. Orville DayLead Physicist
- Mr. Erwin Wong B.Com.Strategic Financial Consultant · born 1968
- Mr. Jeremy PoirierConsultant · born 1986